Hunter is the associate director of cannabinoid research at Canopy Growth Corporation, the largest cannabis producer in the world. Canopy Growth Corporation is a world-leading diversified cannabis company. They operate a collection of diverse brands and curated strain variety, supported millions of square feet of indoor greenhouse production capacity, partnered with some of the leading names in the sector. Previously, Hunter was a global project manager at GW Pharmaceuticals and established its US clinical team. There, Land authored Dravet syndrome, LGS, and multiple-sclerosis protocols and managed the clinical development of the FDA-approved CBD Epidiolex. He speaks at cannabinoid and scientific conferences and collaborates with cannabinoid, neurology, and epilepsy experts, focusing on applications of cannabinoid formulations and their application across a variety of conditions. The land is a co-founder of the Cannabinoid Education Working Group and a member of the International Cannabinoid Research Society, American Epilepsy Society, and the American Academy of Neurology.
Hunter Land: Canopy Growth Corporation (Holiday Special)
